Noetik is a company that applies machine learning to drug discovery, aiming to add complexity to the process.

Noetik

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

NOETIK

Today we are releasing a first glimpse into the work we've been doing internally at NOETIK and sharing some details around OCTO, the first world model of cancer and the tumor microenvironment. 

OCTO is a massively multimodal, transformer-based model trained on proprietary data from thousands of patients’ tumors purpose-built for self supervised learning at NOETIK. It is truly multimodal, ingesting data that includes paired H&E, spatial protein, spatial transcriptomics, and whole exome sequencing for each patient. 

We've desigend OCTO to operate as a simulation engine to power diverse drug discovery tasks from target identification, to biomarker discovery and patient stratification, even prediction of therapeutics response populations.

To find out more about OCTO, read our first technical report: https://www.noetik.ai/octo

Big news today: Incredibly thrilled to announce Shafique Virani, MD FRCS has joined NOETIK as Chief Business Officer! 

Shaf is a world-class leader in drug discovery with decades of experience at innovative large organizations such as Roche, and trailblazing biotechs such as Recursion & BridgeBio. While at Recursion, he led Corporate Development through transformative partnerships with Bayer and Roche/Genentech, including one of the largest and most innovative data-driven partnerships in the space. 

Shaf worked closely with Jacob and Myself, and was a key thought partner, in building the Oncology therapeutic area at Recursion, and again in recruiting critical leaders to establish the Neurosciences platform and therapeutic area. While he is an extraordinary commercial leader, he is also an experienced clinical development leader with a deep commitment to making an impact for patients. 

We're super excited to welcome Shaf to the team!

Read more in our press release:

We're looking for accomplished machine learning engineers to help scale self-supervised models on petabytes of multimodal biological data. If you love understanding distributed systems and have experience building infrastructure for large-scale training and inference, come work with us. Your work will fuel new discoveries in the biological sciences, with the potential to directly impact patients with cancer.

Come build the future with us at NOETIK.

We are rounding out an incredible year at NOETIK. Still a couple days left until the holiday AND so much more going on still. But important to take a moment to reflect on LIGHTSPEED progress of this incredible team. This time last year, we did NOT even have a lab, now today we have built the full discovery platform we envisioned.

Today, we've generated over 600 terabytes of human tumor data including spatial proteomics & transcriptomics, whole exome sequencing, H&E. At the same time we've launched perturb-map for scaled in vivo CRISPR screening. All these data are supported by robust data infrastructure built from the ground up. And these data are training a unique approach to multimodal vision transformers-based world models. And we have already seen that these models can do much more than image reconstruction, they can propose novel targets. 

Importantly, from our three ongoing projects, we are already starting to get to interesting target and therapeutics hypotheses.  

Congratulations to the team on a massively productive year! Excited to unleash this platform to keep building our immunotherapy portfolio next year! 🚀

We're actively scheduling partnering meetings for #JPM2024. Excited to share NOETIK vision to transform oncology drug discovery self supervised machine learning on one of the most unique translational datasets out there. If we're not already scheduled, feel free to reach out. Priority for discovery / clinical biopharma partners and the investment community- no recruiters please. 



#artificialintelligence #drugdiscovery #techbio

Excited to announce another incredible addition to NOETIK team! We are absolutely thrilled to welcome Carl Ebeling to lead our technical operations.  Carl has a ton of experience in massive volume data generation, most recently as VP, Head of Production at Terray Therapeutics. Prior to Terray, he was Director of High Throughput Operations and New Process Implementation at Recursion. Carl has already started important work to increase the data generation capacity of our platform to feed more rich multimodal data to our world models. So excited to work with you again Carl!

AI:NOETIK

Noetik

Financials Not Available